Genetic Epidemiology of Cutaneous Melanoma

Goldstein, Alisa M.; Tucker, Margaret A.

doi:10.1001/archderm.137.11.1493

Cited by 126 publications

(88 citation statements)

References 35 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Individuals from families with a demonstrated history of melanoma are at significant risk for developing this malignancy, representing from 5-12% of all reported cases (Haluska and Hodi, 1998;Goldstein and Tucker, 2001). As early as 1857, William Norris, a British general practitioner, published an article entitled 'Eight cases of Melanosis with Pathological and Therapeutical Remarks on that Disease' (Norris, 1857;Bennett and Hall, 1994).…”

Section: Clinical and Epidemiological Backgroundmentioning

confidence: 99%

Ultraviolet radiation and cutaneous malignant melanoma

2003

View full text Add to dashboard Cite

Recent years have seen a steady rise in the incidence of cutaneous malignant melanoma worldwide. Although it is now appreciated that the key to understanding the process by which melanocytes are transformed into malignant melanoma lies in the interplay between genetic factors and the ultraviolet (UV) spectrum of sunlight, the nature of this relation has remained obscure. Recently, prospects for elucidating the molecular mechanisms underlying such gene-environment interactions have brightened considerably through the development of UV-responsive experimental animal models of melanoma. Genetically engineered mice and human skin xenografts constitute novel platforms upon which to build studies designed to elucidate the pathogenesis of UV-induced melanomagenesis. The future refinement of these in vivo models should provide a wealth of information on the cellular and genetic targets of UV, the pathways responsible for the repair of UV-induced DNA damage, and the molecular interactions between melanocytes and other skin cells in response to UV. It is anticipated that exploitation of these model systems will contribute significantly toward the development of effective approaches to the prevention and treatment of melanoma.

show abstract

Section: Clinical and Epidemiological Backgroundmentioning

confidence: 99%

Ultraviolet radiation and cutaneous malignant melanoma

2003

View full text Add to dashboard Cite

show abstract

“…It is well established that melanoma commonly clusters in families, and in the past two decades, there has been an explosion in research directed at elucidating the genetic basis for melanoma. The recent discovery of several common, albeit low-risk, genotypes has led to the widespread perception that melanoma is a predominantly genetic disease (1).…”

Section: Introductionmentioning

confidence: 99%

Familial Melanoma: A Meta-analysis and Estimates of Attributable Fraction

Olsen

Carroll

Whiteman

2010

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Melanoma commonly clusters in families, and the recent identification of numerous genotypes predicting higher risks of melanoma has led to the widespread perception that this cancer is predominantly a genetic disease. We conducted a systematic review of the literature and meta-analysis to quantify the contribution of familial factors to melanoma, estimated by the population attributable fraction (PAF). Eligible studies were those that permitted quantitative assessment of the association between histologically confirmed melanoma and family history of the disease; we identified 22 such studies using citation databases, followed by manual review of retrieved references. We calculated summary RRs using weighted averages of the log RR, taking into account random effects, and used these to estimate the PAF. Overall, family history was associated with a significant 2-fold increased risk of melanoma (odds ratio, 2.06; 95% confidence interval, 1.72-2.45); however, there was significant heterogeneity (P = 0.01). The pooled estimate for population-based studies (n = 11) was 2.03 (1.70-2.43), and 2.51 (1.55-4.07) for clinic/hospital-based studies (n = 11), both with significant heterogeneity (P = 0.049 and P = 0.013, respectively). Two studies used record linkage to verify family history in relatives; the pooled risk estimate from these two studies was 2.52 (2.11-3.00) with no evidence of heterogeneity (P = 0.258). Estimates of PAF associated with a positive family history ranged from 0.007 for Northern Europe to 0.064 for Australia (0.040 for all regions combined). Our findings suggest that only a small percentage of melanoma cases (always <7%) are attributable to familial risk; the majority of melanomas are presumably attributable to other factors.

show abstract

“…Kialakulásában az ultraibolya sugár-záson kívül a gyermekkori napégéseknek [6], a világos bőr-, szem-és hajszínnek [7], a már meglevő típusos és atípusos naevusok számának (dysplasticus naevus szindróma) [8], családi vagy a személyes anamnézisben szereplő korábbi melanomának és egyéb bőrdaganatnak [9] van jelentősége.…”

Section: A Melanoma Klasszifi Kációjaunclassified

Genetic diversity and immunological characteristics of malignant melanoma: the therapeutic spectrum

Doma

Gulya

2015

Orvosi Hetilap

View full text Add to dashboard Cite

A malignus melanoma pigmentsejtekből kiinduló, későn felfedezve igen agresszív, folyamatosan növekvő incidenciá-jú, bármely korosztályt érintő daganatos megbetegedés. Leggyakoribb formája meglévő hajlamosító tényezők (bőr-, szem-, hajszín, anyajegyek, pozitív családi anamnézis) talaján hozzáadódó környezeti faktorok (napégés) hatására a kültakarón, vagyis minden orvos számára könnyen vizsgálható helyen alakul ki. Sikeres kezelésének alapja továbbra is a korai diagnózis és műtéti eltávolítás. Áttétek jelentkezésekor a klasszikus, bár melanoma esetén csekély sikerrel kecsegtető kemo-és sugárterápia mellett, illetve helyett ma már új, molekuláris genetikai kutatásokon alapuló célzott terápiás szerek, valamint a gátolt tumorellenes immunválaszt a fék alól felszabadító immunterápiás gyógyszerek is rendelkezésre állnak. Az összefoglaló közleményben a szerzők régi és új ismereteket igyekeznek rendszerezni és terjeszteni, bármely, a téma iránt mélyebben érdeklődő gyógyító szakma képviselőjének átnyújtani. Orv. Hetil., 2015, 156(15), 583-591. Kulcsszavak: malignus melanoma, célzott terápia, jelátviteli útvonal, immunterápiaGenetic diversity and immunological characteristics of malignant melanoma: the therapeutic spectrum Malignant melanoma, originating from pigment cells, is a highly aggressive tumour affecting patients of any age group. Its incidence is rapidly growing. The most common form can be easily diagnosed by any physician. There are some well-known genetic (skin-, eye-, hair colour, naevi, melanoma in the personal/family history) and environmental (ultraviolet radiation) predisposing factors. Treatment is based on early diagnosis and excision. When metastasis occurs, the traditional chemo-and radiotherapy gives a low response rate. Recently some newly approved targeted therapies and immunomodulant drugs have become available. This review focuses on the classifi cation and novel therapeutic approaches of malignant melanoma to provide guidance to clinicians.

show abstract

Genetic Epidemiology of Cutaneous Melanoma

Cited by 126 publications

References 35 publications

Ultraviolet radiation and cutaneous malignant melanoma

Ultraviolet radiation and cutaneous malignant melanoma

Familial Melanoma: A Meta-analysis and Estimates of Attributable Fraction

Genetic diversity and immunological characteristics of malignant melanoma: the therapeutic spectrum

Contact Info

Product

Resources

About